Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304625 | 0.87 | ALDH1A1 (0.45) | ALDH1A1TDP1HTTGAASMN1; SMN2 | |
| SCHEMBL304623 | 0.87 | ALDH1A1 (0.45) | ALDH1A1TDP1HTTGAASMN1; SMN2 | |
| SCHEMBL14140962 | 0.83 | ALDH1A1 (0.42) | ALDH1A1TDP1HTTGAASMN1; SMN2 | |
| SCHEMBL800592 | 0.81 | KDM4E (0.35) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL30934386 | 0.76 | ALDH1A1 (0.47) | ALDH1A1TDP1HTTGAASMN1; SMN2 | |
| SCHEMBL65325 | 0.74 | ALDH1A1 (0.53) | ALDH1A1TDP1HTTGAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27501008 | 0.72 | ALDH1A1 (0.56) | ALDH1A1TDP1HTTGAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28645405 | 0.72 | ALDH1A1 (0.56) | ALDH1A1TDP1HTTGAASMN1; SMN2 | |
| SCHEMBL65441 | 0.71 | ALDH1A1 (0.50) | ALDH1A1TDP1HTTGAASMN1; SMN2 | |
| SCHEMBL12226479 | 0.71 | GAA (0.56) | ALDH1A1TDP1HTTGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | MEIJI SEIKA KAISHA (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9260375-B2 | Metallo-β-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | CHIKAUCHI KEN (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ME1, MGAM, GAA | ALDH1A1 372/4885TDP1 2860/4885HTT 4870/4885 |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | ME1, MGAM, MANBA | ALDH1A1 461/4885TDP1 3098/4885HTT 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.